|
시장보고서
상품코드
1786990
세계의 날트렉손 및 부프레노르핀 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 제품별, 투여 경로별, 용도별, 유통 채널별, 지역별 예측(2025-2034년)Naltrexone and Buprenorphine Market Size, Share, Trends, Industry Analysis Report By Product (Naltrexone, Buprenorphine), By Route of Administration, By Application, By Distribution Channel, By Region - Market Forecast, 2025-2034 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면, 세계의 날트렉손 및 부프레노르핀 시장 규모는 2034년까지 124억 달러에 이를 것으로 예측됩니다. 이 보고서는 현재 시장 역학을 상세하게 통찰하고 미래 시장 성장에 대한 분석을 제공합니다.
날트렉손 및 부프레노르핀은 갈증을 줄이고 재발을 예방하여 오피오이드 사용 장애를 치료하는 데 사용되는 약물입니다. 오피오이드 사용 장애의 치료 방법은 단기 해독에서 장기 회복 계획으로 이동하고 있습니다. 헬스케어 전문가들은 약물 치료를 계속함으로써 회복의 성과를 높여 재발의 위험을 낮출 수 있다고 인식하고 있습니다. 날트렉손 및 부프레노르핀은 둘 다 장기적인 치료 전략에 사용되지만, 그 이유는 치료에 대한 참여를 유지하고 약물 사용으로의 회귀 가능성을 줄일 수 있기 때문입니다. 장기적인 접근법을 채택하는 치료 센터가 증가함에 따라, 장기간에 걸쳐 안전하게 복용할 수 있는 약물의 필요성이 증가하고 있습니다. 이 동향은 다양한 치료 환경에서 두 약물의 지속적인 사용을 지원합니다.
기존에 오피오이드 사용 장애의 치료는 주로 중독 전문의가 담당하고 있었지만, 그 상황은 바뀌고 있습니다. 현재, 더 많은 1차 케어 제공업체와 일반 개업 의사가 날트렉손 및 부프레노르핀을 이용한 약물 보조 요법을 제공합니다. 이는 처방 제한이 완화되고 비전문 교육이 강화되었기 때문입니다. 환자는 주치의로부터 치료를 받을 수 있어 치료에 쉽게 접근할 수 있게 되었습니다. 이 변화는 OUD 치료가 일상 건강 관리에 통합되는 것을 돕고 치료를 시작하고 계속할 수있는 환자 수를 증가시키고 있습니다. 접근이 확산됨에 따라, 이러한 약물의 사용은 증가의 길을 따라갈 것으로 예측됩니다.
날트렉손 및 부프레노르핀 시장 보고서 하이라이트
2024년에는 오피오이드의 이탈 증상의 관리나 갈망의 경감에 널리 사용되고 있기 때문에 부프레노르핀 부문이 큰 점유율을 차지합니다.
병원 약국 부문은 과다 복용이나 이탈 증상을 경험한 환자의 첫 번째 케어 포인트이기 때문에 예측 기간 동안 큰 성장이 예상됩니다.
2024년 북미는 날트렉손 및 부프레노르핀 시장에서 가장 큰 점유율을 차지했으며, 오피오이드 사용 장애의 높은 유병률과 치료에 대한 접근성 확대를 위한 정부의 강력한 참여에 견인되었습니다.
아시아태평양의 날트렉손 및 부프레노르핀 시장은 약물 사용 장애에 대한 의식의 향상과 정신 보건 서비스의 강화를 위한 노력으로 현저한 성장을 이루고 있습니다.
세계의 주요 시장 기업으로는 Alkermes, Inc., Camurus, Collegium Pharmaceutical, Indivior PLC, Orexo US, Inc. (a part of Orexo AB), Sun Pharmaceutical Industries Ltd, Titan Pharmaceuticals, Inc. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 날트렉손 및 부프레노르핀 시장 인사이트
- 시장 현황
- 날트렉손 및 부프레노르핀 시장 역학
- 성장 촉진요인과 기회
- 오피오이드 사용 장애 환자 증가
- 정부의 지원 정책과 프로그램
- 억제요인과 과제
- 높은 초기 투자액
- 성장 촉진요인과 기회
- PESTEL 분석
- 날트렉손 및 부프레노르핀 시장 동향
- 밸류체인 분석
제5장 세계의 날트렉손 및 부프레노르핀 시장 : 제품별
- 주요 조사 결과
- 소개
- 날트렉손
- 부프레노르핀
제6장 세계의 날트렉손 및 부프레노르핀 시장 : 투여 경로별
- 주요 조사 결과
- 소개
- 경구 투여
- 주사제 투여
- 이식형 투여
제7장 세계의 날트렉손 및 부프레노르핀 시장 : 용도별
- 주요 조사 결과
- 소개
- 오피오이드 사용 장애(OUD)
- 알코올 사용 장애(AUD)
제8장 세계의 날트렉손 및 부프레노르핀 시장 : 유통 채널별
- 주요 조사 결과
- 소개
- 병원 약국
- 소매 약국
- 기타
제9장 세계의 날트렉손 및 부프레노르핀 시장 : 지역별
- 주요 조사 결과
- 소개
- 날트렉손 및 부프레노르핀 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 제품별, 2020-2034년
- 북미 : 투여 경로별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 북미 : 유통 채널별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 제품별, 2020-2034년
- 유럽 : 투여 경로별, 2020-2034년
- 유럽 : 용도별, 2020-2034년
- 유럽 : 유통 채널별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 제품별, 2020-2034년
- 아시아태평양 : 투여 경로별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 아시아태평양 : 유통 채널별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 제품별, 2020-2034년
- 중동 및 아프리카 : 투여 경로별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 중동 및 아프리카 : 유통 채널별, 2020-2034년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 제품별, 2020-2034년
- 라틴아메리카 : 투여 경로별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 라틴아메리카 : 유통 채널별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제11장 기업 프로파일
- Alkermes, Inc.
- Camurus
- Collegium Pharmaceutical
- Indivior PLC
- Orexo US, Inc.(a part of Orexo AB)
- Sun Pharmaceutical Industries Ltd
- Titan Pharmaceuticals, Inc.
The naltrexone and buprenorphine market size is expected to reach USD 12.40 billion by 2034, according to a new study by Polaris Market Research. The report "Naltrexone and Buprenorphine Market Size, Share, Trends, Industry Analysis Report By Product (Naltrexone, Buprenorphine), By Route of Administration, By Application, By Distribution Channel, By Region- Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Naltrexone and buprenorphine are medications used to treat opioid use disorder by reducing cravings and preventing relapse. There is a shift in how opioid use disorder is being treated from short-term detox to long-term recovery planning. Healthcare professionals now recognize that continued medication support can improve recovery outcomes and lower relapse risks. Naltrexone and buprenorphine are both used in long-term treatment strategies because they help people stay engaged in care and reduce the chance of returning to drug use. As more treatment centers adopt a long-term approach, the need for medications that can be taken safely over time increases. This trend supports continued growth in the use of both medications across various care settings.
Traditionally, treatment for opioid use disorder was handled mostly by addiction specialists, but this is changing. Now, more primary care providers and general practitioners are offering medication-assisted treatment using naltrexone and buprenorphine. This is partly due to reduced prescribing restrictions and increased training for non-specialists. Patients can now receive treatment from their regular doctors, making it easier to access care. This shift is helping integrate OUD treatment into everyday healthcare, which increases the number of patients who can start and continue treatment. As access widens, use of these medications is expected to keep rising.
Naltrexone and Buprenorphine Market Report Highlights
In 2024, the buprenorphine segment dominated with a larger share due to its widespread use in managing opioid withdrawal symptoms and reducing cravings.
The hospitals pharmacies segment is expected to experience significant growth during the forecast period, as hospitals are the first point of care for individuals experiencing overdose or withdrawal.
In 2024, North America dominated the naltrexone and buprenorphine market with the largest share driven by the high prevalence of opioid use disorder and strong government involvement in expanding access to treatment.
The Asia Pacific naltrexone and buprenorphine market is experiencing significant growth, due to growing awareness of substance use disorders and efforts to strengthen mental health services.
A few global key market players are Alkermes, Inc.; Camurus; Collegium Pharmaceutical; Indivior PLC; Orexo US, Inc. (a part of Orexo AB); Sun Pharmaceutical Industries Ltd; and Titan Pharmaceuticals, Inc.
Polaris market research has segmented the naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:
By Product (Revenue - USD Billion, 2020-2034)
Naltrexone
Buprenorphine
BELBUCA
Sublocade
Suboxone
Zubsolv
Others
By Route of Administration (Revenue - USD Billion, 2020-2034)
Oral Administration
Injectable Administration
Implantable Administration
By Application (Revenue - USD Billion, 2020-2034)
Opioid Use Disorder (OUD)
Alcohol Use Disorder (AUD)
By Distribution Channel (Revenue - USD Billion, 2020-2034)
Hospitals Pharmacies
Retail Pharmacies
Others
By Regional Outlook (Revenue - USD Billion, 2020-2034)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of APAC
Latin America
Argentina
Brazil
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of MEA
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Naltrexone And Buprenorphine Market Insights
- 4.1. Naltrexone And Buprenorphine Market - Market Snapshot
- 4.2. Naltrexone And Buprenorphine Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing Number of People with Opioid Use Disorder
- 4.2.1.2. Supportive Government Policies and Programs
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Initial Investment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Naltrexone And Buprenorphine Market Trends
- 4.6. Value Chain Analysis
5. Global Naltrexone And Buprenorphine Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 5.3. Naltrexone
- 5.3.1. Global Naltrexone And Buprenorphine Market, by Naltrexone, by Region, 2020-2034 (USD billion)
- 5.4. Buprenorphine
- 5.4.1. Global Naltrexone And Buprenorphine Market, by Buprenorphine, by Region, 2020-2034 (USD billion)
- 5.4.2. BELBUCA
- 5.4.2.1. Global Naltrexone And Buprenorphine Market, by BELBUCA, by Region, 2020-2034 (USD billion)
- 5.4.3. Sublocade
- 5.4.3.1. Global Naltrexone And Buprenorphine Market, by Sublocade, by Region, 2020-2034 (USD billion)
- 5.4.4. Suboxone
- 5.4.4.1. Global Naltrexone And Buprenorphine Market, by Suboxone, by Region, 2020-2034 (USD billion)
- 5.4.5. Zubsolv
- 5.4.5.1. Global Naltrexone And Buprenorphine Market, by Zubsolv, by Region, 2020-2034 (USD billion)
- 5.4.6. Others
- 5.4.6.1. Global Naltrexone And Buprenorphine Market, by Others, by Region, 2020-2034 (USD billion)
6. Global Naltrexone And Buprenorphine Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 6.3. Oral Administration
- 6.3.1. Global Naltrexone And Buprenorphine Market, by Oral Administration, by Region, 2020-2034 (USD billion)
- 6.4. Injectable Administration
- 6.4.1. Global Naltrexone And Buprenorphine Market, by Injectable Administration, by Region, 2020-2034 (USD billion)
- 6.5. Implantable Administration
- 6.5.1. Global Naltrexone And Buprenorphine Market, by Implantable Administration, by Region, 2020-2034 (USD billion)
7. Global Naltrexone And Buprenorphine Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Naltrexone And Buprenorphine Market, by Medical Biotechnology, 2020-2034 (USD billion)
- 7.3. Opioid use disorder (OUD)
- 7.3.1. Global Naltrexone And Buprenorphine Market, by Opioid use disorder (OUD), by Region, 2020-2034 (USD billion)
- 7.4. Alcohol use disorder (AUD)
- 7.4.1. Global Naltrexone And Buprenorphine Market, by Alcohol use disorder (AUD), by Region, 2020-2034 (USD billion)
8. Global Naltrexone And Buprenorphine Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 8.3. Hospitals Pharmacies
- 8.3.1. Global Naltrexone And Buprenorphine Market, by Hospitals Pharmacies, by Region, 2020-2034 (USD billion)
- 8.4. Retail Pharmacies
- 8.4.1. Global Naltrexone And Buprenorphine Market, by Retail Pharmacies, by Region, 2020-2034 (USD billion)
- 8.5. Others
- 8.5.1. Global Naltrexone And Buprenorphine Market, by Others, by Region, 2020-2034 (USD billion)
9. Global Naltrexone And Buprenorphine Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Naltrexone And Buprenorphine Market Assessment, By Geography, 2020-2034 (USD billion)
- 9.3. Naltrexone And Buprenorphine Market - North America
- 9.3.1. North America: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.3.2. North America: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.3.3. North America: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.3.4. North America: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.3.5. Naltrexone And Buprenorphine Market - US
- 9.3.5.1. US: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.3.5.2. US: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.3.5.3. US: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.3.5.4. US: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.3.6. Naltrexone And Buprenorphine Market - Canada
- 9.3.6.1. Canada: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.3.6.2. Canada: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.3.6.3. Canada: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.3.6.4. Canada: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4. Naltrexone And Buprenorphine Market - Europe
- 9.4.1. Europe: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.2. Europe: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.3. Europe: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.4. Europe: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.5. Naltrexone And Buprenorphine Market - UK
- 9.4.5.1. UK: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.5.2. UK: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.5.3. UK: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.5.4. UK: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.6. Naltrexone And Buprenorphine Market - France
- 9.4.6.1. France: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.6.2. France: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.6.3. France: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.6.4. France: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.7. Naltrexone And Buprenorphine Market - Germany
- 9.4.7.1. Germany: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.7.2. Germany: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.7.3. Germany: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.7.4. Germany: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.8. Naltrexone And Buprenorphine Market - Italy
- 9.4.8.1. Italy: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.8.2. Italy: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.8.3. Italy: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.8.4. Italy: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.9. Naltrexone And Buprenorphine Market - Spain
- 9.4.9.1. Spain: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.9.2. Spain: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.9.3. Spain: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.9.4. Spain: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.10. Naltrexone And Buprenorphine Market - Netherlands
- 9.4.10.1. Netherlands: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.10.2. Netherlands: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.10.3. Netherlands: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.10.4. Netherlands: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.11. Naltrexone And Buprenorphine Market - Russia
- 9.4.11.1. Russia: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.11.2. Russia: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.11.3. Russia: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.11.4. Russia: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.4.12. Naltrexone And Buprenorphine Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.4.12.2. Rest of Europe: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.4.12.3. Rest of Europe: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.4.12.4. Rest of Europe: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5. Naltrexone And Buprenorphine Market - Asia Pacific
- 9.5.1. Asia Pacific: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.2. Asia Pacific: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.3. Asia Pacific: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.4. Asia Pacific: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.5. Naltrexone And Buprenorphine Market - China
- 9.5.5.1. China: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.5.2. China: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.5.3. China: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.5.4. China: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.6. Naltrexone And Buprenorphine Market - India
- 9.5.6.1. India: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.6.2. India: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.6.3. India: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.6.4. India: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.7. Naltrexone And Buprenorphine Market - Malaysia
- 9.5.7.1. Malaysia: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.7.2. Malaysia: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.7.3. Malaysia: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.7.4. Malaysia: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.8. Naltrexone And Buprenorphine Market - Japan
- 9.5.8.1. Japan: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.8.2. Japan: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.8.3. Japan: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.8.4. Japan: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.9. Naltrexone And Buprenorphine Market - Indonesia
- 9.5.9.1. Indonesia: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.9.2. Indonesia: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.9.3. Indonesia: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.9.4. Indonesia: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.10. Naltrexone And Buprenorphine Market - South Korea
- 9.5.10.1. South Korea: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.10.2. South Korea: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.10.3. South Korea: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.10.4. South Korea: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.11. Naltrexone And Buprenorphine Market - Australia
- 9.5.11.1. Australia: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.11.2. Australia: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.11.3. Australia: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.11.4. Australia: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.5.12. Naltrexone And Buprenorphine Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.5.12.2. Rest of Asia Pacific: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.5.12.3. Rest of Asia Pacific: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.5.12.4. Rest of Asia Pacific: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.6. Naltrexone And Buprenorphine Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.6.2. Middle East & Africa: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.6.3. Middle East & Africa: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.6.4. Middle East & Africa: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.6.5. Naltrexone And Buprenorphine Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.6.5.2. Saudi Arabia: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.6.5.3. Saudi Arabia: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.6.5.4. Saudi Arabia: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.6.6. Naltrexone And Buprenorphine Market - UAE
- 9.6.6.1. UAE: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.6.6.2. UAE: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.6.6.3. UAE: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.6.6.4. UAE: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.6.7. Naltrexone And Buprenorphine Market - Israel
- 9.6.7.1. Israel: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.6.7.2. Israel: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.6.7.3. Israel: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.6.7.4. Israel: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.6.8. Naltrexone And Buprenorphine Market - South Africa
- 9.6.8.1. South Africa: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.6.8.2. South Africa: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.6.8.3. South Africa: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.6.8.4. South Africa: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.6.9. Naltrexone And Buprenorphine Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.6.9.2. Rest of Middle East & Africa: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.6.9.3. Rest of Middle East & Africa: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.6.9.4. Rest of Middle East & Africa: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.7. Naltrexone And Buprenorphine Market - Latin America
- 9.7.1. Latin America: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.7.2. Latin America: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.7.3. Latin America: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.7.4. Latin America: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.7.5. Naltrexone And Buprenorphine Market - Mexico
- 9.7.5.1. Mexico: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.7.5.2. Mexico: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.7.5.3. Mexico: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.7.5.4. Mexico: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.7.6. Naltrexone And Buprenorphine Market - Brazil
- 9.7.6.1. Brazil: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.7.6.2. Brazil: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.7.6.3. Brazil: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.7.6.4. Brazil: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.7.7. Naltrexone And Buprenorphine Market - Argentina
- 9.7.7.1. Argentina: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.7.7.2. Argentina: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.7.7.3. Argentina: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.7.7.4. Argentina: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
- 9.7.8. Naltrexone And Buprenorphine Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Naltrexone And Buprenorphine Market, by Product, 2020-2034 (USD billion)
- 9.7.8.2. Rest of Latin America: Naltrexone And Buprenorphine Market, by Route of Administration, 2020-2034 (USD billion)
- 9.7.8.3. Rest of Latin America: Naltrexone And Buprenorphine Market, by Application, 2020-2034 (USD billion)
- 9.7.8.4. Rest of Latin America: Naltrexone And Buprenorphine Market, by Distribution Channel, 2020-2034 (USD billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Alkermes, Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Camurus
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Collegium Pharmaceutical
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Indivior PLC
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Orexo US, Inc. (a part of Orexo AB)
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Sun Pharmaceutical Industries Ltd
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Titan Pharmaceuticals, Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
샘플 요청 목록